Literature DB >> 23214280

Calcitonin and procalcitonin in patients with medullary thyroid cancer or bacterial infection.

Krzysztof Kaczka1, Sławomir Mikosiński, Wojciech Fendler, Agnieszka Celnik, Lech Pomorski.   

Abstract

OBJECTIVES: To evaluate procalcitonin (PCT) utility as a marker of medullary thyroid cancer (MTC).
MATERIAL AND METHODS: Calcitonin (CT) and PCT levels were measured in MTC patients and patients with serious bacterial infections. 70 patients were enrolled in the study: 6 MTC active patients: 4 with disseminated, unreoperable disease and 2 re-operated patients, in whom markers were checked before and after surgery; 23 MTC patients in remission after radical surgery; 11 non-toxic nodular goiter (NTNG) patients; 30 patients with severe, bacterial infection or sepsis.
RESULTS: All MTC active patients had greatly elevated CT and PCT levels. In two re-operated patients, marker levels decreased but were still above the reference range. In 15 MTC patients in remission, the levels of either marker were not increased. Both markers were slightly increased in 3 patients in this group, while CT was elevated in 5 patients. In all but 1 patient in the NTNG group, both marker levels were not elevated. Among patients with bacterial infection, PCT and CT levels showed no increase in 8 patients, both markers were elevated in 10 patients, and an increase of PCT levels was seen in 10 patients while of CT only in 2 patients. Correlations between CT and PCT values were very strong in MTC patients (r = 0.95; p = 0.004 for active MTC, r = 0.60; p = 0.002 for MTC patients in remission) and in patients with NTNG (r = 0.77; p = 0.02). In patients with infection, both parameters were completely independent (r = 0.002; p = 0.99).
CONCLUSIONS: PCT measurement could be an alternative to CT measurement for evaluation of MTC status.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23214280

Source DB:  PubMed          Journal:  Adv Clin Exp Med        ISSN: 1899-5276            Impact factor:   1.727


  8 in total

Review 1.  Overview of procalcitonin in pregnancy and in pre-eclampsia.

Authors:  A Mangogna; C Agostinis; G Ricci; F Romano; R Bulla
Journal:  Clin Exp Immunol       Date:  2019-06-13       Impact factor: 4.330

2.  The relationship between procalcitonin and thyroid autoantibodies in patients with autoimmune thyroiditis.

Authors:  Ali Oncul; Ihsan Ates; Mehmet Fettah Arikan; Nisbet Yilmaz; Canan Topcuoglu; Fatma Meric Yilmaz; Mustafa Altay
Journal:  J Clin Lab Anal       Date:  2017-02-07       Impact factor: 2.352

3.  Case report of severe Cushing's syndrome in medullary thyroid cancer complicated by functional diabetes insipidus, aortic dissection, jejunal intussusception, and paraneoplastic dysautonomia: remission with sorafenib without reduction in cortisol concentration.

Authors:  Muhammad M Hammami; Najla Duaiji; Ghazi Mutairi; Sabah Aklabi; Nasser Qattan; Mohei El-Din M Abouzied; Mohamed W Sous
Journal:  BMC Cancer       Date:  2015-09-09       Impact factor: 4.430

Review 4.  Utility of blood procalcitonin concentration in the management of cancer patients with infections.

Authors:  Bonita Durnaś; Marzena Wątek; Tomasz Wollny; Katarzyna Niemirowicz; Michał Marzec; Robert Bucki; Stanisław Góźdź
Journal:  Onco Targets Ther       Date:  2016-01-22       Impact factor: 4.147

5.  Procalcitonin as Marker of Recurrent Medullary Thyroid Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Pierpaolo Trimboli; Luca Giovanella
Journal:  Endocrinol Metab (Seoul)       Date:  2018-06

6.  Diagnostic Value of Procalcitonin in ANCA-Associated Vasculitis (AAV) to Differentiate Between Disease Activity, Infection and Drug Hypersensitivity.

Authors:  K Herrmann; S Schinke; E Csernok; F Moosig; J U Holle
Journal:  Open Rheumatol J       Date:  2015-10-09

Review 7.  Esophageal neuroendocrine carcinoma complicated with unexpected hyperprocalcitonin: Case report and literature review.

Authors:  Qida Hu; Piaopiao Jin; Xinyu Zhao; Wangteng Wu; Bingfeng Huang; Shiyi Shao; Risheng Que; Tingbo Liang
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

8.  Basal and Calcium-Stimulated Procalcitonin for the Diagnosis of Medullary Thyroid Cancers: Lights and Shadows.

Authors:  Simona Censi; Marta Di Stefano; Andrea Repaci; Teresa Benvenuti; Jacopo Manso; Uberto Pagotto; Maurizio Iacobone; Susi Barollo; Loris Bertazza; Francesca Galuppini; Clara Benna; Gianmaria Pennelli; Mario Plebani; Diego Faggian; Carla Colombo; Laura Fugazzola; Caterina Mian
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-13       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.